Email Updates

Search form

You are here

GSK3732394: A Multi-Specific Inhibitor of HIV Entry

Include in
Published Research

Long-acting antiretrovirals could provide a useful alternative to daily oral therapy for HIV-1 infected individuals. Building on a bi-specific molecule with adnectins targeting CD4 and gp41, a potential long-acting biologic, GSK3732394, was developed with three independent and synergistic modes of HIV entry inhibition that potentially could be self-administered as a long-acting subcutaneous injection.

August 2, 2019
Journal of Virology